Mid-Trimester (13-20 Weeks) Maternal Serum β HCG As a Predictor of Hypertensive Disorders of Pregnancy

Abstract

Background: Hypertensive disorders of pregnancy are a significant contributor to maternal mortality, with early identification of risk factors being crucial for proactive management. This study explores the potential of mid-trimester maternal serum β HCG levels as a predictive marker for hypertensive disorders during pregnancy. Objective: The primary objective of this prospective study was to evaluate the clinical utility of second-trimester serum β HCG levels in predicting the development of hypertensive disorders during pregnancy. Methods: The study, conducted from June 2020 to July 2021, recruited pregnant women aged 13-20 weeks who were normotensive and non-proteinuric. Data from 100 respondents were collected, with 50 in each group (Group A with β HCG > 35000 m IU/ml and Group B with β HCG < 35000 m IU/ml). Statistical analysis was performed using SPSS 24.0, and the significance level was set at p < 0.05. Results: Group A had a significantly higher proportion of hypertensive disorders compared to Group B (38% vs. 10%, p < 0.001), with Group A being more than five times as likely to develop hypertensive disorders (cOR = 5.5, 95% CI: 1.862, 16.344). Serum β HCG levels in respondents with hypertensive disorders (Mean = 60626.88 m IU/ml) were significantly higher than those who were normotensive (Mean = 32812.18 m IU/ml, p < 0.001). Sensitivity was 79.17%, specificity was 59.21%, and positive and negative predictive values were 38% and 90%, respectively. Conclusions: Mid-trimester serum β HCG levels are an efficient non-invasive predictor of hypertensive disorders during pregnancy. With its high sensitivity and negative predictive value, this cost-effective test can aid in the early identification and proactive management of at-risk pregnancies.